Intratumoral immunization by p19arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma

Translational Oncology

Volumn 9, Issue 6, 2016, Pages 565-574

  Catani, João Paulo Portela ^a   Medrano, Ruan F V ^a   Hunger, Aline ^a   Valle, Paulo Del ^a   Adjemian, Sandy ^a   Zanatta, Daniela Bertolini ^a   Kroemer, Guido ^{b,c,d,e,f,g,h}   Costanzi Strauss, Eugenia ^a   Strauss, Bryan E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CALRETICULIN; CISPLATIN; CXCL3 CHEMOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NUTLIN 3; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN MDM2; PROTEIN P19; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; CANCER IMMUNIZATION; CANCER INFILTRATION; CELL DEATH; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE THERAPY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 85000893462     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2016.09.011     Document Type: Article

References (74)

1. Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, and Liu D (2012). Recent advances and novel agents for gastrointestinal stromal tumor GIST. J Hematol Oncol 5, 21
2. Lin Y, Wang X, and Jin H (2014). EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4, 411-435
3. Mitsudomi T, Suda K, and Yatabe Y (2013). Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol 10, 235-244
4. Gajria D and Chandarlapaty S (2011). HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11, 263-275
5. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, and Wolchok JD (2015). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 33, 1889-1894
6. Marabelle A, Kohrt H, and Levy R (2013). Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 19, 5261-5263
7. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, and Brody J, et al (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123, 2447-2463
8. Fransen MF, van der Sluis TC, Ossendorp F, Arens R, and Melief CJ (2013). Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 19, 5381-5389
9. Zbar B and Tanaka T (1971). Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172, 271-273
10. Thompson ED, Enriquez HL, Fu YX, and Engelhard VH (2010). Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 207, 1791-1804
11. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, and Steegh K, et al (2013). Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729-741
12. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, and Lee HW, et al (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92, 713-723
13. Zhang Y, Xiong Y, and Yarbrough WG (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734
14. Brown CJ, Lain S, Verma CS, Fersht AR, and Lane DP (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9, 862-873
15. Cirone M, Garufi A, Di Renzo L, Granato M, Faggioni A, and D’Orazi G (2013). Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology 2, e26198
16. Huang Y, Tyler T, Saadatmandi N, Lee C, Borgstrom P, and Gjerset RA (2003). Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability [erratum appears in Cancer Res. 2003 Aug 15; 63(16):5171]. Cancer Res 63, 3646-3653
17. Ozenne P, Eymin B, Brambilla E, and Gazzeri S (2010). The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127, 2239-2247
18. Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, Commo F, Girard P, Fouret P, and Brambilla E, et al (2014). Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas. Clin Lung Cancer 15, 124-130
19. Tagawa M, Tada Y, Shimada H, and Hiroshima K (2013). Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer Gene Ther 20, 150-156
20. Milojkovic A, Hemmati PG, Muer A, Overkamp T, Chumduri C, Janicke RU, Gillissen B, and Daniel PT (2013). p14ARF induces apoptosis via an entirely caspase-3-dependent mitochondrial amplification loop. Int J Cancer 133, 2551-2562
21. Bai Y, Lu Z, Lin Y, Sun B, Wang S, and Wang G (2013). Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias. Oncol Res 21, 23-31
22. Xian J, Lin Y, Liu Y, Gong P, and Liu S (2007). Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma LSCC. DNA Cell Biol 26, 71-79
23. Merkel CA, Medrano RF, Barauna VG, and Strauss BE (2013). Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Ther 20, 317-325
24. Kalvakolanu DV (2003). Alternate interferon signaling pathways. Pharmacol Ther 100, 1-29
25. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, and Borden EC (2003). Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237-249
26. Bracarda S, Eggermont AM, and Samuelsson J (2010). Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 46, 284-297
27. Maeda S, Wada H, Naito Y, Nagano H, Simmons S, Kagawa Y, Naito A, Kikuta J, Ishii T, and Tomimaru Y, et al (2014). Interferon-alpha acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem 289, 23786-23795
28. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, and Honda K, et al (2003). Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516-523
29. Rogge L, D’Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, Adorini L, and Sinigaglia F (1998). The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 161, 6567-6574
30. Biron CA, Nguyen KB, Pien GC, Cousens LP, and Salazar-Mather TP (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17, 189-220
31. Salazar-Mather TP, Lewis CA, and Biron CA (2002). Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1alpha delivery to the liver. J Clin Invest 110, 321-330
32. Blanco P, Palucka AK, Gill M, Pascual V, and Banchereau J (2001). Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294, 1540-1543
33. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, and Darga T, et al (2014). STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843-852
34. Lim JY, Gerber SA, Murphy SP, and Lord EM (2014). Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63, 259-271
35. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, and Remedios C, et al (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20, 1301-1309
36. Oh SS, Moon C, Kim DH, Song H, Park S, Fu Y, and Kim KD (2012). Adenovirally delivered IFN-beta exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation. Int J Mol Med 29, 1153-1157
37. Huang H, Xiao T, He L, Ji H, and Liu XY (2012). Interferon-beta-armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells. Acta Biochim Biophys Sin Shanghai 44, 737-745
38. Park MY, Kim DR, Jung HW, Yoon HI, Lee JH, and Lee CT (2010). Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta. Cancer Gene Ther 17, 356-364
39. Shih CS, Laurie N, Holzmacher J, Spence Y, Nathwani AC, Davidoff AM, and Dyer MA (2009). AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med 11, 43-52
40. Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, and Yoshida J (2008). A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med 10, 329-339
41. Medrano RF, Catani JP, Ribeiro AH, Tomaz SL, Merkel CA, Costanzi-Strauss E, and Strauss BE (2016). Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy. Cancer Immunol Immunother 65, 371-382
42. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA, and Hayakawa T (2001). A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 8, 730-735
43. Bajgelman MC and Strauss BE (2008). Development of an adenoviral vector with robust expression driven by p53. Virology 371, 8-13
44. Peng HH, Wu S, Davis JJ, Wang L, Roth JA, Marini III FC, and Fang B (2006). A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. Anal Biochem 354, 140-147
45. Mitchell CH, Carre DA, McGlinn AM, Stone RA, and Civan MM (1998). A release mechanism for stored ATP in ocular ciliary epithelial cells. Proc Natl Acad Sci U S A 95, 7174-7178
46. Hansen EL, Sozer EB, Romeo S, Frandsen SK, Vernier PT, and Gehl J (2015). Dose-dependent ATP depletion and cancer cell death following calcium electroporation, relative effect of calcium concentration and electric field strength. PLoS One 10, e0122973
47. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, and Kroemer G (2011). Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30, 61-69
48. Vanneman M and Dranoff G (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12, 237-251
49. Hammerich L, Binder A, and Brody JD (2015). In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9, 1966-1981
50. Bohle A and Brandau S (2003). Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170, 964-969
51. Pierce RH, Campbell JS, Pai SI, Brody JD, and Kohrt HE (2015). In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother 11, 1901-1909
52. Swiatek-Koscielna B, Kaluzna EM, Januszkiewicz-Lewandowska D, Rembowska J, Mozer-Lisewska I, Bereszynska I, Czubala K, Dziechciowska K, Wysocka-Leszczynska J, and Barcinska D, et al (2015). HCV infection and interferon-based treatment induce p53 gene transcription in chronic hepatitis C patients. Viral Immunol 28, 434-441
53. Forys JT, Kuzmicki CE, Saporita AJ, Winkeler CL, Maggi Jr. LB, and Weber JD (2014). ARF and p53 coordinate tumor suppression of an oncogenic IFN-beta-STAT1-ISG15 signaling axis. Cell Rep 7, 514-526
54. Chiantore MV, Vannucchi S, Accardi R, Tommasino M, Percario ZA, Vaccari G, Affabris E, Fiorucci G, and Romeo G (2012). Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS One 7, e36909
55. Galluzzi L, Kepp O, and Kroemer G (2013). Immunogenic cell death in radiation therapy. Oncoimmunology 2, e26536
56. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, and Bloy N, et al (2014). Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691
57. Johnston B, Burns AR, Suematsu M, Issekutz TB, Woodman RC, and Kubes P (1999). Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1. J Clin Invest 103, 1269-1276
58. Reichel CA, Rehberg M, Lerchenberger M, Berberich N, Bihari P, Khandoga AG, Zahler S, and Krombach F (2009). Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol 29, 1787-1793
59. Elazar S, Gonen E, Livneh-Kol A, Rosenshine I, and Shpigel NY (2010). Neutrophil recruitment in endotoxin-induced murine mastitis is strictly dependent on mammary alveolar macrophages. Vet Res 41, 10
60. Nolan KF, Strong V, Soler D, Fairchild PJ, Cobbold SP, Croxton R, Gonzalo JA, Rubio A, Wells M, and Waldmann H (2004). IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals. J Immunol 172, 2201-2209
61. Eigenbrod T, Park JH, Harder J, Iwakura Y, and Nunez G (2008). Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol 181, 8194-8198
62. Erlandsson Harris H and Andersson U (2004). Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34, 1503-1512
63. Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X, Loike JD, Jenkins RE, Antoine DJ, and Schwabe RF (2015). The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest 125, 539-550
64. Tadie JM, Bae HB, Jiang S, Park DW, Bell CP, Yang H, Pittet JF, Tracey K, Thannickal VJ, and Abraham E, et al (2013). HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4. Am J Physiol Lung Cell Mol Physiol 304, L342-L349
65. Azab BM, Dash R, Das SK, Bhutia SK, Sarkar S, Shen XN, Quinn BA, Dent P, Dmitriev IP, and Wang XY, et al (2014). Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus Ad.5/3-CTV. J Cell Physiol 229, 34-43
66. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, and Kao GD, et al (2009). The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8, 2221-2231
67. Piccard H, Muschel RJ, and Opdenakker G (2012). On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 82, 296-309
68. Mantovani A, Cassatella MA, Costantini C, and Jaillon S (2011). Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11, 519-531
69. Lim K, Hyun YM, Lambert-Emo K, Capece T, Bae S, Miller R, Topham DJ, and Kim M (2015). Neutrophil trails guide influenza-specific CD8(+) T cells in the airways. Science 349, aaa4352
70. Abi Abdallah DS, Egan CE, Butcher BA, and Denkers EY (2011). Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol 23, 317-326
71. Reali E, Guerrini R, Moretti S, Spisani S, Lanza F, Tomatis R, Traniello S, and Gavioli R (1996). Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. J Leukoc Biol 60, 207-213
72. Ueda R, Narumi K, Hashimoto H, Miyakawa R, Okusaka T, and Aoki K (2016). Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipients. Cancer Med 5, 49-60
73. Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, and Hel Z (2014). Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog 10, e1003993
74. de Kleijn S, Langereis JD, Leentjens J, Kox M, Netea MG, Koenderman L, Ferwerda G, Pickkers P, and Hermans PW (2013). IFN-gamma-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One 8, e72249